Research & Development

Scientific Approach

Phynova has identified a number of Drug Candidates in the fields of anti-virals, anti-microbials, anti-inflammatories and oncology. At present, it is concentrating its development efforts on six of these: PYN17, PYN22, PYN9, PYN6, PYN18 and PYN7.

Phynova intends to develop these Drug Candidates by conducting pre-clinical tests and in some cases clinical trials. Phynova will then seek to out-license the Drug Candidates to major pharmaceutical companies. By selecting Drug Candidates whose efficacy and safety have already been established in China, Phynova expects to be able to reduce the time taken to bring the drugs to market. Similarly, it hopes to be able to take advantage of the US FDA's recent Guidance for Industry- 'Botanical Drug Products', 2004 (http://www.fda.gov/cder/guidance/4592fnl.htm) and, where possible, to fast track the registration of its Drug Candidates.